Sangamo Therapeutics, Inc.SGMONASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +425.77% | +269.78% | +1238.25% | +5042.13% | -98.82% |
| Gross Profit Growth | +0.00% | +269.78% | +1238.25% | +5042.13% | -98.82% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | -360.17% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -434.43% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -427.31% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | -344.44% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | -351.14% |
| Weighted Average Shares Growth | +17.60% | +18.33% | +22.14% | +25.99% | +46.04% |
| Weighted Average Shares Diluted Growth | +20.97% | +18.33% | +22.14% | +25.99% | +41.97% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -342.35% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | -345.29% |
| Receivables Growth | +499.77% | +13.06% | +567.00% | +756.45% | -51.17% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -49.36% | -38.52% | -33.18% | +4.89% | -20.33% |
| Book Value per Share Growth | -75.34% | -76.79% | -92.92% | -34.32% | -89.08% |
| Debt Growth | -20.72% | -19.78% | -19.28% | -19.37% | -8.31% |
| R&D Expense Growth | -51.42% | -53.31% | -27.54% | +11.81% | +1.48% |
| SG&A Expenses Growth | -20.61% | -24.68% | -14.52% | -24.64% | -27.67% |